<DOC>
	<DOCNO>NCT00670189</DOCNO>
	<brief_summary>The purpose study determine safety BMS-833923 ( XL139 ) patient advance metastatic cancer determine recommend phase 2 dose range schedule</brief_summary>
	<brief_title>A Phase 1 Study BMS-833923 ( XL139 ) Subjects With Advanced Metastatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Basal Cell</mesh_term>
	<criteria>For additional information , please contact BMS oncology clinical trial information service 8552160126 email MyCancerStudyConnect @ emergingmed.com . Please visit www.BMSStudyConnect.com information clinical trial participation . Advanced metastatic cancer ( exclude cancer blood ) uncontrolled basal cell nevoid syndrome sporadic basal cell carcinoma Primary metastatic tumor site accessible biopsy Ability swallow capsule Subjects histologically confirm , advanced stage IIIB stage IV nonsmall cell lung cancer ( NSCLC ) primary histology squamous carcinoma receive prior systemic therapy advance NSCLC enrol Part 3 Uncontrolled brain metastasis Significant cardiovascular disease Inadequate blood count Inadequate liver , kidney lung function Gastrointestinal disease within last 3 month Infection Human Immunodeficiency Virus ( HIV ) , Hepatitis B Hepatitis C exposure attenuate active immunization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>